---
layout: default
title: Arnica Montana Whole Arsenic Tribromide Arsenic Tr
parent: 僅模型預測 (L5)
nav_order: 370
evidence_level: L5
indication_count: 0
---

# Arnica Montana Whole Arsenic Tribromide Arsenic Tr
{: .fs-9 }

證據等級: **L5** | 預測適應症: **0** 個
{: .fs-6 .fw-300 }

---

## 目錄
{: .no_toc .text-delta }

1. TOC
{:toc}

---

<div id="pharmacist">

## 藥師評估報告

</div>

# Multi-Ingredient Homeopathic Combination: No Repurposing Prediction Available

## One-Sentence Summary

This candidate consists of 13 botanical, zoological, and mineral ingredients characteristic of a homeopathic combination product (including Arnica Montana, Saw Palmetto, Shark Cartilage, and a Human Breast Tumor Cell nosode), with no approved indication on record.
The TxGNN pipeline returned **no predicted indications** for this candidate, likely because the multi-ingredient string could not be mapped to a single DrugBank entity.
Without a valid DrugBank ID, TxGNN score, or regulatory baseline, a standard repurposing evaluation cannot proceed.

---

## Quick Overview

| Item | Content |
|------|---------|
| Original Indication | None on record |
| Predicted New Indication | None — TxGNN returned no results |
| TxGNN Prediction Score | N/A |
| Evidence Level | L5 — Model prediction only (no actual studies linked) |
| US Market Status | Not marketed |
| Number of NDAs | 0 |
| Recommended Decision | **Hold** |

---

## Why is This Prediction Reasonable?

No TxGNN prediction was generated for this candidate, so there is no repurposing hypothesis to evaluate.

The input string contains 13 distinct ingredients spanning herbal extracts (Arnica Montana, Saw Palmetto, Thymus Serpyllum), mineral/arsenic homeopathic dilutions (Arsenic Tribromide, Arsenic Triiodide), zoological sources (Asterias Rubens, Bufo Bufo Cutaneous Gland, Shark Cartilage), and a Human Breast Tumor Cell nosode — a profile consistent with a homeopathic combination remedy. Because the TxGNN knowledge graph operates on single-entity DrugBank IDs, a multi-component string of this type cannot be meaningfully embedded or scored.

A repurposing analysis would only become feasible if: (1) the product is dissolved into its individual pharmacologically active constituents and each is evaluated separately, or (2) the product is reframed as a single registered entity with a confirmed DrugBank ID.

---

## Clinical Trial Evidence

Currently no related clinical trials registered.

---

## Literature Evidence

Currently no related literature available.

---

## Safety Considerations

Please refer to the package insert for safety information.

> No DDI data, warnings, or contraindication records were returned for this multi-ingredient query. Individual component safety profiles (e.g., arsenic compounds, Strychnos alkaloids) warrant independent review before any clinical use.

---

## Conclusion and Next Steps

**Decision: Hold**

**Rationale:**
The candidate ID resolves to a 13-ingredient homeopathic combination with no DrugBank ID, no approved indication, and no TxGNN prediction output — the minimum data requirements for a repurposing evaluation are not met.

**To proceed, the following is needed:**

- **Entity disambiguation**: Identify whether this combination is registered as a single product under a known brand name; if so, retrieve the corresponding DrugBank ID.
- **Component-level evaluation**: If individual active ingredients are of interest (e.g., Thymol, Choline, Saw Palmetto extract), submit each as a separate query with its own DrugBank ID.
- **Regulatory baseline**: Confirm the approved indication (or lack thereof) through the originating regulatory authority to establish a repurposing starting point.
- **Arsenic compound safety review**: Arsenic Tribromide and Arsenic Triiodide require dedicated toxicological assessment regardless of homeopathic dilution claims before any further evaluation.
- **MOA documentation**: Without a mechanism of action, the biological plausibility of any future prediction cannot be assessed.
## Disclaimer

This content is for research purposes only and does not constitute medical advice.
Clinical validation is required before any clinical application.

---

